AstraZeneca has announced promising results from the BATURA Phase IIIb trial, showcasing the effectiveness of AIRSUPRA ...

Honeywell Solstice® Air can cut metered dose inhaler greenhouse gas emissions of up to 99.9% versus current propellants1 CHARLOTTE, N.C., October, 2024 – Honeywell (NASDAQ: HON) today announced a long ...

An initial list of 101 generic drugs available to those enrolled in the government's Medicare program for no more than $2 for ...

Topline results were announced from a trial evaluating albuterol/budesonide inhaler in patients with intermittent or mild persistent asthma.

"AstraZeneca’s Phase III trial of treatment for asthma meets its primary endpoint" was originally created and published by ...

AstraZeneca’s BATURA phase IIIb trial of Airsupra in patients with intermittent or mild persistent asthma meets primary endpoint: Cambridge, UK Tuesday, October 8, 2024, 09:00 H ...

In the phase 3b BATURA trial, Airsupra—a pressurized metered-dose inhaler containing albuterol and budesonide—significantly ...

AstraZeneca's Airsupra (albuterol/budesonide) met the primary endpoint in the Phase III BATURA trial, significantly reducing ...

AstraZeneca’s inhaled rescue medication, Airsupra (albuterol/budesonide), has shown significant efficacy in reducing the risk of severe asthma exacerbations in patients with intermittent or mild ...

AstraZeneca’s inhaled rescue medication, Airsupra (albuterol/budesonide), has shown significant efficacy in reducing the risk of severe asthma exacerbations in patients with intermittent or mild ...

(Alliance News) - AstraZeneca PLC on Monday said an independent data monitoring committee recommended an early trial stop for its medication Airsupra due to overwhelming efficacy at pre-planned ...

Levalbuterol and albuterol act quickly to open your airways during an asthma attack. Find out more about key differences and ...